Lifitegrast
- Generic Name
- Lifitegrast
- Brand Names
- Xiidra
- Drug Type
- Small Molecule
- Chemical Formula
- C29H24Cl2N2O7S
- CAS Number
- 1025967-78-5
- Unique Ingredient Identifier
- 038E5L962W
- Background
Lifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome). It is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist that was discovered through the rational design process. The ophthalmic solution was approved in July, 2016 under the trade name Xiidra. It has shown ...
- Indication
适用于治疗干眼病（DED）的症状和体征。
- Associated Conditions
- Dry Eye Syndrome (DES)
- Associated Therapies
- -
A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye
- First Posted Date
- 2012-12-06
- Last Posted Date
- 2021-06-23
- Lead Sponsor
- Shire
- Target Recruit Count
- 720
- Registration Number
- NCT01743729
- Locations
- 🇺🇸
OPUS-2 Investigational Site, Norfolk, Virginia, United States
🇺🇸OPUS-2 Investigational SIte, Rancho Cordova, California, United States
Safety Study of Lifitegrast to Treat Dry Eye
- First Posted Date
- 2012-07-10
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- Shire
- Target Recruit Count
- 332
- Registration Number
- NCT01636206
- Locations
- 🇺🇸
SONATA Investigational Site, Houston, Texas, United States
Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1)
- Conditions
- Interventions
- First Posted Date
- 2011-08-22
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- Shire
- Target Recruit Count
- 588
- Registration Number
- NCT01421498
- Locations
- 🇺🇸
OPUS-1 Investigational Site, Norfolk, Virginia, United States
A Study Evaluating the Efficacy of SAR 1118 (0.1%, 1.0%, 5.0%) Ophthalmic Solution in Subjects With Dry Eye Conducted in a Controlled Adverse Environment (CAE)
- First Posted Date
- 2009-06-23
- Last Posted Date
- 2021-08-09
- Lead Sponsor
- Shire
- Target Recruit Count
- 230
- Registration Number
- NCT00926185
- Locations
- 🇺🇸
Mundorf Eye Center, Charlotte, North Carolina, United States
🇺🇸The Eye Care Group, Waterbury, Connecticut, United States
🇺🇸Central Maine Eye Care, Lewiston, Maine, United States
Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis
- First Posted Date
- 2009-04-16
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- Shire
- Target Recruit Count
- 60
- Registration Number
- NCT00882687
- Locations
- 🇺🇸
Ora, Andover, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.